t3011
Biologicalexperimental
Clinical trial activity
12 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Apr 21, 2020 (NCT05602792)
Timeline
Indications
Studied for
- Ascites · Phase 1
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Melanoma · Phase 2
- Mesothelioma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06971614 | Phase 2 | Jun 9, 2025 | ImmVira Pharma Co. Ltd |
| NCT06283303 | Phase 1 | Apr 2, 2024 | China Medical University |
| NCT06214156 | Phase 1/Phase 2 (Phase 2) | Jan 26, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT06214143 | Phase 1/Phase 2 (Phase 2) | Jan 11, 2024 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT06200376 | Phase 1 | Sep 28, 2023 | Sichuan University |
| NCT06200363 | Phase 1 | Sep 21, 2023 | Sichuan University |
| NCT06427291 | Phase 1 | Sep 21, 2023 | Fudan University |
| NCT05756556 | Phase 2 | Jun 30, 2023 | ImmVira Pharma Co. Ltd |
| NCT05598268 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2022 | ImmVira Pharma Co. Ltd |
| NCT04780217 | Phase 1/Phase 2 (Phase 2) | Aug 10, 2021 | ImmVira Pharma Co. Ltd |
| NCT04370587 | Phase 1 | Jul 31, 2020 | ImmVira Pharma Co. Ltd |
| NCT05602792 | Phase 1/Phase 2 (Phase 2) | Apr 21, 2020 | ImmVira Pharma Co. Ltd |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmVira Pharma Co. Ltd | For profit | 6 | 6 | 2 | 2020 |
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 2 | 2 | 1 | 2024 |
| Sichuan University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1